Overview
Hao-Fountain syndrome (also known as Hao-Fountain syndrome due to USP7 mutation, or USP7-related neurodevelopmental disorder) is a rare genetic condition caused by heterozygous loss-of-function mutations or deletions in the USP7 gene (ubiquitin-specific peptidase 7) located on chromosome 16p13.2. USP7 encodes a deubiquitinating enzyme involved in multiple cellular pathways, including regulation of the tumor suppressor p53 and epigenetic modification through interaction with the Polycomb repressive complex. Loss of USP7 function disrupts normal neurodevelopment and multiple organ systems. The syndrome is characterized primarily by intellectual disability and developmental delay of variable severity, speech and language difficulties, and behavioral abnormalities including features of autism spectrum disorder, anxiety, and attention deficit. Affected individuals frequently exhibit hypotonia (low muscle tone), feeding difficulties in infancy, and seizures. Additional features may include hypogonadism, cryptorchidism in males, eye abnormalities, and nonspecific dysmorphic facial features such as a broad forehead, widely spaced eyes, and a thin upper lip. Some patients also demonstrate abnormalities in brain MRI imaging, including white matter changes. There is currently no cure or targeted therapy for Hao-Fountain syndrome. Management is supportive and multidisciplinary, focusing on early intervention services including speech therapy, occupational therapy, physical therapy, and behavioral support. Seizures are managed with standard antiepileptic medications. Endocrine abnormalities such as hypogonadism may require hormonal treatment. Regular developmental assessments and monitoring by a team including neurologists, endocrinologists, and developmental pediatricians are recommended. Research into the molecular mechanisms of USP7 dysfunction is ongoing and may eventually inform more targeted therapeutic approaches.
Also known as:
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Infantile
Begins in infancy, roughly 1 month to 2 years old
Treatments
No FDA-approved treatments are currently listed for Hao-Fountain syndrome due to USP7 mutation.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Hao-Fountain syndrome due to USP7 mutation at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Hao-Fountain syndrome due to USP7 mutation.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Hao-Fountain syndrome due to USP7 mutation.
Community
No community posts yet. Be the first to share your experience with Hao-Fountain syndrome due to USP7 mutation.
Start the conversation →Latest news about Hao-Fountain syndrome due to USP7 mutation
No recent news articles for Hao-Fountain syndrome due to USP7 mutation.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Hao-Fountain syndrome due to USP7 mutation
What is Hao-Fountain syndrome due to USP7 mutation?
Hao-Fountain syndrome (also known as Hao-Fountain syndrome due to USP7 mutation, or USP7-related neurodevelopmental disorder) is a rare genetic condition caused by heterozygous loss-of-function mutations or deletions in the USP7 gene (ubiquitin-specific peptidase 7) located on chromosome 16p13.2. USP7 encodes a deubiquitinating enzyme involved in multiple cellular pathways, including regulation of the tumor suppressor p53 and epigenetic modification through interaction with the Polycomb repressive complex. Loss of USP7 function disrupts normal neurodevelopment and multiple organ systems. The
How is Hao-Fountain syndrome due to USP7 mutation inherited?
Hao-Fountain syndrome due to USP7 mutation follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Hao-Fountain syndrome due to USP7 mutation typically begin?
Typical onset of Hao-Fountain syndrome due to USP7 mutation is infantile. Age of onset can vary across affected individuals.